Onvansertib + FOLFIRI/Bevacizumab
RAS-mutated Metastatic Colorectal Cancer (2L+)
Phase 2Active
Key Facts
Indication
RAS-mutated Metastatic Colorectal Cancer (2L+)
Phase
Phase 2
Status
Active
Company
About Cardiff Oncology
Cardiff Oncology's mission is to develop novel cancer therapies by leveraging Polo-like kinase 1 (PLK1) inhibition. Its core achievement is advancing its lead asset, onvansertib, into multiple mid-stage clinical trials in combination with standard regimens for difficult-to-treat cancers like metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC). The company's strategy is predicated on using onvansertib to target tumor vulnerabilities and overcome resistance to existing therapies, aiming to deliver superior clinical benefit. Cardiff's future is entirely tied to the clinical validation of this combination approach.
View full company profile